Menu
Search
|

Menu

Close
X

Voyager Therapeutics Inc VYGR.OQ (NASDAQ Stock Exchange Global Select Market)

26.69 USD
+3.03 (+12.81%)
As of 12:10 PM EST
chart
Previous Close 23.66
Open 24.33
Volume 133,392
3m Avg Volume 170,528
Today’s High 26.90
Today’s Low 23.30
52 Week High 26.90
52 Week Low 8.10
Shares Outstanding (mil) 26.95
Market Capitalization (mil) 637.63
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.62 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY17
4
FY16
14
FY15
17
EPS (USD)
FY17
-2.265
FY16
-1.586
FY15
-1.489
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
103.66
8.67
Price to Book (MRQ)
vs sector
7.29
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
0.00
15.38
LT Debt to Equity (MRQ)
vs sector
0.00
12.01
Return on Investment (TTM)
vs sector
-48.61
13.57
Return on Equity (TTM)
vs sector
-62.77
15.19

EXECUTIVE LEADERSHIP

Mark Levin
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Steven Paul
President, Chief Executive Officer, Director, Since 2014
Salary: $150,000.00
Bonus: --
Jane Henderson
Chief Financial Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
Matthew Ottmer
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Robert Pietrusko
Senior Vice President - Regulatory Affairs, Since 2014
Salary: $174,792.00
Bonus: $1,161.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

75 Sidney St
CAMBRIDGE   MA   02139-4134

Phone: +1857.2595340

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company's pipeline consists of programs for CNS indications, including advanced Parkinson's disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington's disease; Friedreich's ataxia; frontotemporal dementia/Alzheimer's disease, and severe chronic pain. The Company's clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson's disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

SPONSORED STORIES